3 results
Approved WMOCompleted
Currently, caplacizumab is being developed for treatment of acquired thrombotic thrombocytopenic purpura (TTP). TTP is a rare and potentially life-threatening thrombotic microangiopathy, in which accumulation of ULvWF multimers leads to an increased…
Approved WMOWill not start
Primary Objective:* To evaluate the effect of every-other-week subcutaneous (SC) administration of XmAb5871 on the time to IgG4-related disease (IgG4-RD) disease flare following an initial course of corticosteroid therapy in subjects with active…
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)